A crucial question of this study was: “How did pre-existing factors in resected GBM wt modify patient eligibility for a followed oncotherapy” Our aim was to identify clinical and biologically relevant prognostic factors for IDH wt GBM, to propose biological mechanisms explaining why these factors affect prognosis, and to identify clinically relevant IDH wt GBM subgroups. This evidence concerns the gene IDH1 and glioblastoma.